As genomics are playing an increasing role in drug development, CROs need to expand their capabilities to stay relevant, Quintiles CEO Tom Pike said. "Genetic sequencing is going to become more a part of clinical trials," Pike told Triangle Business Journal. "We're working closely to integrate (it) into our lab business and our clinical trial business." Naturally, Pike was mum on the swelling rumors that Quintiles is plotting an IPO, but he did say the company will pursue a few acquisitions in the future but focus on organic growth. Report